Trial · NCT05164549
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Count of days abstinent From illicit/non-medical opioids during weeks 2 to 24 (range: 0-161 days) | 24 weeks | Combining self-report information from Time-Line Follow-Back interview adapted from the Treatment Outcomes Profile and incorporating data from 12 scheduled urine drug screens. |
| Secondary | Clinical superiority of XR-Bup plus PSI versus Bup/Met plus PSI | 24 weeks | Number of days abstinent from cocaine Days 8 - 168 Number of days abstinent from Benzodiazepines Days 8 - 168 Longest time in days continuously abstinent from heroin Days 8 - 168 Longest time in days continuously abstinent from cocaine Days 8 - 168 Longest time in days continuously abstinent from Benzodiazepines Days 8 - 168 |
| Secondary | Cost-effectiveness of XR-BUP versus Bup and Met | 24 weeks | Based on the incremental cost per quality-adjusted life year (QALY) gained. |
| Secondary | Safety of XR-Bup | 24 weeks | Number of safety events from study enrolment to 24 weeks |
| Secondary | Time (days) enrolled in study treatment (retention) to week 24 | 24 weeks | |
| Secondary | OUD remission status (DSM5 OUD severity; SCID-5-RV) | 24 weeks | |
| Secondary | Clinician rating of severity, complexity and recovery strengths: ADAPT | 24 weeks | |
| Secondary | Clinician global impression of severity and improvement): CGI-S/I; | 24 weeks | |
| Secondary | Count of days abstinent from cocaine and illicit/non-medical benzodiazepines | 24 weeks | During weeks 2 to 24 (range: 0-161 days); combining self-report information from Time-Line Follow-Back interview adapted from the Treatment Outcomes Profile and incorporating data from 12 scheduled urine drug screens |
| Secondary | Frequency of opioid (H) and cocaine (C) craving experience: CEQ-F(H) and CEQ-F(C) | 24 weeks | |
| Secondary | Craving need and want strength for heroin and cocaine: VAS-N(H/C) and VAS-W(H/C) | 24 weeks | |
| Secondary | Difficulties in Emotion Regulation (Short Form): DERS-SF | 24 weeks | |
| Secondary | Depression symptoms: QIDS-SR | 24 weeks | |
| Secondary | Work and social adjustment: WSAS | 24 weeks | |
| Secondary | Subjective recovery and improvement: SURE | 24 weeks | |
| Secondary | Patient rating of OUD severity and improvement: | 24 weeks | Utilising PRO-S/I; |
| Secondary | Patient rating of OUD severity and improvement: | 24 weeks | Cognitive impairment: MoCA |
| Secondary | Alcohol consumption: typical quantity and frequency: (ALC-QFM) | 24 weeks | |
| Secondary | Longer Term Outcomes | Through study completion, up to 4 years | Among participants enrolled in longer term XR-BUP treatment: heroin, cocaine and illicit/non-medical benzodiazepine use in past 90 days (TLFB; UDS) |
| Secondary | Longer Term Outcomes | Through study completion, up to 4 years | Among participants enrolled in longer term XR-BUP treatment: OUD and CUD remission status (SCID-5-RV) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05164549/registered